Solara Active Pharma Sciences Limited — Board Meeting, 24-01-2025: Outcome of Board Meeting

The Board of Solara Active Pharma Sciences Limited has approved the exploration of a potential demerger of its CRAMS and Polymers business into an independent entity. This strategic move aims to enhance focus and operational efficiency within the respective sectors. Alongside, the company released its financial results for the quarter and nine months ending December 31, 2024, showcasing revenues of ₹301.8 crore (up 21% YoY) and a notable gross margin of 55%. With EBITDA margins improving to 19.6%, the firm maintains its EBITDA guidance for FY25 between ₹230-260 crore.